GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health

Germany will be the first launch market

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO

Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India

Huwel’s diagnostic solutions leverage open RT-PCR system

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints